Research programme: cell therapies - Green Cross Cell Corporation

Drug Profile

Research programme: cell therapies - Green Cross Cell Corporation

Alternative Names: Autoimmune disease therapy - Green Cross Cell; Autoimmune disease therapy - Innocell; Dendritic cell therapy - Green Cross Cell; Dendritic cell therapy - Innocell; Regulatory T cell therapy - Green Cross Cell; Regulatory T cell therapy - Innocell; Stem cell therapy - Green Cross Cell; Stem cell therapy - Innocell

Latest Information Update: 31 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innocell Corporation
  • Developer Green Cross Cell
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Dendritic cell stimulants; Regulatory T-lymphocyte stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 31 May 2016 Preclinical development is ongoing in South Korea
  • 09 Sep 2013 Preclinical development is ongoing in South Korea
  • 22 Mar 2013 Innocell Corporation is now called Green Cross Cell Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top